NCT05234489View on ClinicalTrials.gov

Study to Assess Signature Cord Product in Patients With Symptomatic OA of the Knee

PHASE1UnknownINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 1, 2022

Primary Completion Date

June 30, 2023

Study Completion Date

June 30, 2023

Conditions
Osteoarthritis, Knee
Interventions
BIOLOGICAL

Signature Cord Prime

"Low dose - Subjects will receive SIG001 (75 mg) which will be diluted to a total of 4 ml volume with Ringer's Lactate.~High dose - Subjects will receive SIG001 (150mg) which will be diluted to a total of 4 ml volume with Ringer's Lactate."

Sponsors

Collaborators (1)

KLM Solutions, LLC
All Listed Sponsors
collaborator

Signature Biologics, LLC

UNKNOWN

collaborator

KLM Solutions, LLC

UNKNOWN

lead

Thomas Klootwyk, MD

OTHER